Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
bluebird bio has completed the spin-off of its oncology programs into the new business entity, 2seventy bio, Inc, which will begin trading on the Nasdaq this morning under the ticker symbol “TSVT.”
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Moderna reported its third-quarter earnings, and since it currently only has one commercial product, its COVID-19 vaccine, that was the financial focus.
Isomorphic Laboratories has expressed plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
The proceeds will be used to advance the development of their ePLC platform, treatment for chronic Hepatitis B, and a novel class of anti-cancer therapies.
The job cuts, which affect a variety of functions and levels, are expected to slow its cash burn rate and leave the company with sufficient funds on hand to operate until mid-2023.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
This agreement would cap out-of-pocket costs for insulin at $35 a month and all out-of-pocket medical costs for seniors at $2,000 a year.